Oxford BioTherapeutics

Who: Roche and Oxford BioTherapeutics What: The Swiss major has entered into a multi-year collaboration with OBT to develop first-in-class antibody-based therapeutics for the treatment of cancer.

Novartis AG took another step toward catching up with its peers in the cell therapy space with a partnership with Legend Biotech Corp. to develop CAR-T cells for solid tumors, particularly lung and

Like many of its large pharma peers, Boehringer Ingelheim GmbH likes to talk about its lofty research and development goals and sourcing external innovation to stay on the cutting edge of therapeuti

Like many of its large pharma peers, Boehringer Ingelheim likes to talk about its lofty research and development goals and sourcing external innovation to stay on the cutting edge of therapeutic mod